A mixture of: isomers of 2-(2H-benzotriazol-2-yl)-4-methyl-(n)-dodecylphenol; isomers of 2-(2H-benzotriazol-2-yl)-4-methyl-(n)-tetracosylphenol; isomers of 2-(2H-benzotriazol-2-yl)-4-methyl-5,6-didodecyl-phenol. n=5 or 6

Basic toxicokinetics

Administrative data

Endpoint:

basic toxicokinetics

Type of information:

experimental study

Adequacy of study:

key study

Study period:

18.05.2006 - 10.07.2007

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2007

Report date:

2007

Materials and methods

Objective of study:

toxicokinetics

Test guideline

Qualifier:

equivalent or similar to guideline

Guideline:

OECD Guideline 417 (Toxicokinetics)

Version / remarks:

The study was based on partially fulfilling the requirements of the guideline

Principles of method if other than guideline:

The objective of this study was: To determine whether the test article is absorbed following oral administration.

GLP compliance:

yes (incl. QA statement)

Test material

Test material information

Constituent 1

Reference substance name:

A mixture of: isomers of 2-(2H-benzotriazol-2-yl)-4-methyl-(n)-dodecylphenol; isomers of 2-(2H-benzotriazol-2-yl)-4-methyl-(n)-tetracosylphenol; isomers of 2-(2H-benzotriazol-2-yl)-4-methyl-5,6-didodecyl-phenol. n=5 or 6

EC Number:

401-680-5

EC Name:

A mixture of: isomers of 2-(2H-benzotriazol-2-yl)-4-methyl-(n)-dodecylphenol; isomers of 2-(2H-benzotriazol-2-yl)-4-methyl-(n)-tetracosylphenol; isomers of 2-(2H-benzotriazol-2-yl)-4-methyl-5,6-didodecyl-phenol. n=5 or 6

Cas Number:

125304-04-3

Molecular formula:

C25 H35 N3 O and C37 H59 N3 O

IUPAC Name:

Reaction mass of 2-(2H-benzotriazol-2-yl)-4-methyl-(n)-dodecylphenol, branched and 2-(2H-benzotriazol-2-yl)-4-methyl-5,6-didodecyl-phenol, branched

Radiolabelling:

yes

Test animals

Species:

rat

Strain:

Sprague-Dawley

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: in-house, animals were received at the research laboratory
- Age at study initiation: males: ca. 6-7 weeks; females ca. 8-9 weeks
- Weight at study initiation: males: 187 - 225 g, females: 186-229 g
- Fasting period before study: no
- Housing: housed individually in glass metabolism cages (Metabowls)
- Individual metabolism cages: yes
- Diet: VRFI diet, ad libitum
- Water: from local water supply, ad libitum
- Acclimation period: at least 5 days prior to dosing

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21 +/- 2
- Humidity (%): 55 +/- 15
- Air changes (per hr): approx. 15
- Photoperiod: 12 hrs dark / 12 hrs light

IN-LIFE DATES: 31.05. - 06.09.2006

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

other: 4 % carboxymethylcellulose and 0.2 % Tween 80

Details on exposure:

PREPARATION OF DOSING SOLUTIONS:
Dose formulations were freshly prepared for administration to groups of animals. Where required radiolabelled and non-radiolabelled test item were mixed together in ethyl acetate to achieve the desired specific activity for the dosed material. For all other dose groups, the radiolabelled test item was not radiodiluted. The solvent was removed under a stream of nitrogen and the solid material suspended in 2% (w/v) aqueous carboxymethylcellulose solution / 0.2% Tween 80, using a magnetic stirrer.
The quantity of radioactivity administered to each animal was determined from the weight of the administered formulation (based on the weight of the dosing syringe before and after dosing) and the measured concentration of radioactivity in the formulation. Further weighed portions of the dose formulation were either counted directly by LSC or dispensed into 20 or 25 mL volumetric flasks. These were made up to volume with methanol and triplicate aliquots of each solution taken for radioactivity measurement. The specific activity of the [14C]-test item in the high level formulation was calculated from the radioactivity concentration of the formulation (taking into account the specific activity of the undiluted test item) and the weight of non-radiolabelled test item in the formulation.
The nominal radioactivity contained in each dose (50 mg/kg groups) was 20 µCi per rat (200 g).

VEHICLE
- Amount of vehicle (if gavage): 10 mL/kg bw

HOMOGENEITY AND STABILITY OF TEST MATERIAL:
At least triplicate aliquots of each dose formulation were analyzed for radioactivity to confirm the homogeneity of the formulation and the actual dose level. The dose formulation were analyzed for stability of the test substance after dosing.

Duration and frequency of treatment / exposure:

All animals received a single dose via oral gavage.

Doses / concentrations

Doses / concentrations 1

Dose / conc.:

0.5 mg/kg bw/day

Remarks:

Group 1: Excretion/tissue distribution, sacrifice 168h

Doses / concentrations 2

Dose / conc.:

50 mg/kg bw/day

Remarks:

Group 2: Excretion/tissue distribution, sacrifice 168h

Doses / concentrations 3

Dose / conc.:

0.5 mg/kg bw/day

Remarks:

Group 3: Tissue distribution, sacrifice 6h

Doses / concentrations 4

Dose / conc.:

50 mg/kg bw/day

Remarks:

Group 4: Tissue distribution, sacrifice 6h

No. of animals per sex per dose / concentration:

4

Control animals:

no

Positive control reference chemical:

None

Details on study design:

- Dose selection rationale: Dose levels have been selected after consultation with the appropriate Regulatory Authority, the BfR, and have been set at levels which would cause no observable effects (NOEL).

Details on dosing and sampling:

PHARMACOKINETIC STUDY (Absorption, distribution, excretion)
- Tissues and body fluids sampled: urine, cage wash, faeces, plasma, whole-blood, fat, muscle, brain, heart, kidney, liver, lungs, spleen, testes, ovaries, uterus, gastrointestinal tract, carcass
- Time and frequency of sampling:
urine: 0-6, 6-24, 24-48, 48-72, 72-96, 96-120, 120-144, 144-168 hrs after administration
faeces: 0-24, 24-48,48-72, 72-96, 96-120, 120-144, 144-168 hours after administration
volatiles: 0-24 hrs after the administration
all others: 168 hrs after administration

Statistics:

The mean and standard deviation were used to characterise the data, where appropriate (i.e., radioactivity measurement, concentrations, etc.). Concentrations of radioactivity in blood, plasma and tissues were calculated as µg equivalents of test item/g of sample. The total amounts of radioactivity in tissue and excreta samples were calculated as a percentage of the administered radioactivity and a 14C mass balance is presented. Individual excretion half-lives (t ½) were calculated by linear regression of time versus log concentration curves for urine and faeces.

Results and discussion

Main ADME results

Main ADME results 1

Type:

absorption

Results:

Absorption based on values in urine, expired air and tissues was low.

Main ADME results 2

Type:

distribution

Results:

After 6hrs (high and low dose level): liver > spleen > ovaries > all others; after 168 hrs (high and low dose level): ovaries > liver > fat > all others

Main ADME results 3

Type:

excretion

Results:

Mainly via faeces and in a lower extend via urine and negligibly via expired air.

Toxicokinetic / pharmacokinetic studies

Details on absorption:

Absorption values in urine, expired air and tissues was low (1-3 % dose).

Details on distribution in tissues:

- 168 hours
0.5 mg/kg bw and 50 mg/kg bw test item:
Following administration of [phenyl-14C]-test item, very little of the administered radioactivity (< 1 %) was retained in the tissues at 168 hours. The highest accumulation occurred in the ovaries, liver and fat. There was less than a proportional increase in tissue concentrations of radioactivity at the high dose level.

- 6 hours
0.5 mg/kg bw test item:
Following administration of [phenyl-14C]-test item at 0.5 mg/kg bw (low level), a mean of less than 8 % administered radioactivity was retained in the tissues other than gastrointestinal tract (including contents) at 6 hours. Most of the retained radioactivity was detected in the liver (7 % dose). The highest concentrations occurred in the liver, spleen and ovaries.
50 mg/kg bw test item:
At 6 hours following administration of [phenyl-14C]-test item at 50 mg/kg bw (high level), a mean of 3 % administered radioactivity was retained in the tissues other than gastrointestinal tract and contents. Most of the retained radioactivity was detected in the liver (3 % dose). The highest concentrations occurred in the liver, spleen and ovaries.

Details on excretion:

After administration of [14C]-test item at the low and high dose levels, < 1 % dose was excreted in the urine and 93 - 96 % was excreted in the faeces. More than 77 % dose was excreted in the faeces during 0 - 24 hours after dose administration. Most of the radioactivity (>90 %) was excreted within the first 48 hours after administration.

Metabolite characterisation studies

Metabolites identified:

not measured